scout
|Videos|January 30, 2023

Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME